

Win Min Han¹, Bastian Neesgaard², Michael Knappik³, Matthias Cavassini⁴, Irene Abela⁵, Alisa Timiryasova², Lauren Greenberg², Charlotte Martin⁶, Cristina Mussini⁷, Ferdinand Wit⁸, Caroline Sabin⁹, Antonella Castagna¹⁰, Akaki Abutidze¹¹, Wafaa El-Sadr¹², Fabrice Bonnet¹³, Mario Sarcletti¹⁴, Christina Carlander¹⁵, Anna Hachfeld¹⁶, Nina Weis¹⁷, Vani Vannappagari¹⁸, Felipe Rogatto¹⁹, Lital Young²⁰, Sean Hosein²¹, Lene Ryom^{2,22,23}, Kathy Petoumenos¹, on behalf of the D:A:D and RESPOND collaborations

1.Kirby Institute, UNSW Sydney, Sydney, Australia. 2.CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 3.Department of Respiratory Medicine, Klinik Penzing, Vienna, Austria. 4. Service of Infectious Diseases, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. 5. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich. 6.Infectious Diseases Department, Saint-Pierre University Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium. 7. Università degli Studi di Modena, Modena, Italy. 8. AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort, HIV Monitoring Foundation, Amsterdam, the Netherlands. 9. Institute for Global Health, University College London, London, UK. 10. San Raffaele Scientific Institute, Università Vita-Salute San Raffaele, Milano, Italy. 11. Georgian National AIDS Health Information System (AIDS HIS), Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia. 12.Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA. 13. CHU de Bordeaux and Bordeaux University, BPH, INSERM U1219, Bordeaux, France. 14. Austrian HIV Cohort Study, Department of Dermatology and Venerology, Medical University Innsbruck, Innsbruck, Austria. 15.Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden. 16. Department of Infectious Diseases, University Hospital Bern, University of Bern, Bern, Switzerland. 17. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. 18. ViiV Healthcare, Durham, USA. 19. Gilead science, Foster City, USA. 20. Merck Sharp & Dohme, Rahway, New Jersey, USA. 21. European AIDS Treatment Group (EATG). 22. Department of Infectious Diseases, Hvidovre University Hospital, Copenhagen, Denmark. 23. Department of Clinical medicine, University of Copenhagen, Copenhagen, Denmark.

BACKGROUND

- In the general population, the incidence of cancer is increasing among women while declining trends have been observed among men.¹
- There is little information on the incidence of cancers, or associated risk factors, among women with HIV.
- We therefore investigated cancer incidence in women with HIV in two large international HIV cohort collaborations (D:A:D and RESPOND) between 2006 and 2022.

METHODS

- We included all women (sex assigned at birth) ≥18 years and investigated the incidence of, and risk factors for:
 - the **most common cancers combined lung, breast, non-Hodgkin's lymphoma, cervical, anal, head & neck and other non-cervical gynecological cancers**
 - **cancers specifically for women breast (although men can have breast cancers), cervical and other gynecological cancers**
 - **HPV-related cancers cervical, head & neck, other noncervical HPV-related gynecological and anal cancers**
- Cancers in RESPOND and D:A:D are/were reported using study-specific cancer event forms and undergo/underwent central validation
- Baseline was defined as the latest of the date into a local cohort enrolment, or 1st January 2006 for the D:A:D cohort, and 1st January 2012 for the RESPOND cohort.
- Crude incidence rates (95% confidence intervals, CI) of each cancer group were determined and multivariable Poisson regression with robust standard errors was used to assess factors associated with cancers. We also investigated the interactions between key variables such as age and CD4 counts.

Reference

1. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA: A Cancer Journal for Clinicians **2025**; 75(1): 10-45.

Women with HIV older than 45 years, particularly those with past and/or current immunosuppression or current smokers, are at an increased risk of cancers. This population should be considered for more intensified cancer screening and prevention strategies.

RESULTS

- Among **17,512 women** included, most were recruited from Western Europe cohorts (45%), and 27% were ART-naïve. At baseline, median (interquartile range, IQR) age was 40 years (IQR 33-46), baseline and pre-ART nadir CD4 count were 458 (306-654) and 223 (110-363) cells/μL, respectively, and 21% had a prior AIDS diagnosis (of which 14% were AIDS-defining cancers).
- Over 141,404 person-years (PY, median 9.2 [5.5-10.1] years) of follow-up:
 - **539 women had one of the common cancers - incidence rate 3.8 [95%CI, 3.5-4.2]/1000 PY**
 - **291 women had a women-specific cancer (2.1 [1.8-2.3]/1000 PY) and 163 had an HPV-related cancer (1.1 [1.0-1.3]/1000 PY) (Figure)**




Figure. Cancer incidence rates in women with HIV, stratified by regions (A) and age groups (B)

Most common cancer group included 149 breast, 83 cervical, 91 lung cancers, 70 non-Hodgkin's lymphoma, 58 non-cervical gynecological cancers, 46 head & neck cancers and 42 anal cancers. **Women-specific cancer group** included 149 breast cancers, 83 cervical and 59 non-cervical other gynecological cancers, while **HPV-related cancer group** included 43 anal, 83 cervical, 28 non-cervical HPV-related gynecological cancers (3 vaginal and 25 vulval cancers) and 9 head & neck cancers (all were oropharyngeal cancers). Note: 2 women experienced multiple cancers and therefore, the number of cancers included in each group are not the same.

RESULTS (cont.)

- In adjusted analyses, **older age** (45-55 years, incidence rate ratio, IRR: 2.10, [95% CI 1.71-2.59] and >55 years, IRR: 2.52 [1.96-3.24], vs. <45 years), **history of injecting drug use** (IRR: 1.34 [1.00-1.83]), those located in **Southern Europe** (IRR: 1.41 [1.13-1.76], vs. Western Europe) and **current smoking** (IRR: 1.93 [1.48-2.50]) were associated with an **increased risk of the most common cancers**.
- **Higher pre-ART nadir CD4 counts**, (IRR: 0.73 [0.56-0.74] >350 vs <200 cells/μL), **higher current CD4 counts** (350-499, IRR: 0.75 [0.57-0.97], 500-749, IRR: 0.70 [0.55-0.89] and ≥750, IRR: 0.69 [0.54-0.89], vs. <350 cells/μL) were **associated with a reduced risk, while prior AIDS events** (IRR: 1.48 [1.23-1.77]) were associated with an **increased risk of most common cancers, as well as the heightened risk for HPV-related and lung cancers**. No significant interactions were found between current CD4 counts and age groups when evaluating risk factors of the most common cancers ($P_{interaction}=0.37$).

CONCLUSIONS

- The most common incident cancers in women with HIV in the combined D:A:D and RESPOND collaborations were breast, lung and cervical cancers.
- Our study suggests that women, **particularly those with past and/or current immunosuppression**, may benefit from intensified cancer prevention and screening measures where available, in addition to the currently recommended screening groups, such as older individuals and smokers.

ACKNOWLEDGMENTS

The authors acknowledge the participation of all people with HIV recruited to RESPOND and D:A:D study cohorts.

RESPOND and D:A:D are/were both supported by The CHU St Pierre Brussels HIV Cohort, The Australian HIV Observational Database, The AIDS Therapy Evaluation in the Netherlands National Observational HIV cohort, The EuroSIDAc cohort, The Nice HIV Cohort, The ICONA Foundation, The Swiss HIV Cohort Study. RESPOND is also supported by The Austrian HIV Cohort Study, The Frankfurt HIV Cohort Study, The Georgian National AIDS Health Information System, The Modena HIV Cohort, The PISCIS Cohort Study, The Royal Free HIV Cohort Study, The San Raffaele Scientific Institute, The Swedish InfCareHIV Cohort, The University Hospital Bonn HIV Cohort, The University of Cologne HIV Cohort, The Brighton HIV Cohort and The National Croatian HIV cohort and financially supported by ViiV Healthcare, Merck Life Sciences, Gilead Sciences. D:A:D was supported by the Aquitaine cohort, the BASS cohort, the Community Programs for Clinical Research on AIDS, and the HIV-BIVUS and was financially funded by the Highly Active Antiretroviral Therapy Oversight Committee, a collaborative committee with representation from academic institutions, the European Agency for the Evaluation of Medicinal Products, the United States Food and Drug Administration, the patient community, and pharmaceutical companies with licensed anti-HIV drugs in the European Union: AbbVie, Bristol-Myers Squibb, Gilead Sciences Inc., ViiV Healthcare, Merck & Co Inc., Janssen Pharmaceuticals.